6月17日，ImmunityBio盘中下跌5.12%，报6.765美元/股，成交额6831.55万美元。
消息面上，公司近期因核心药物Anktiva的营销合规问题收到FDA处方药推广办公室（OPDP）正式警告信，指出公司以误导性方式推广该IL-15受体激动剂药物，此前FDA已两度发出"无标题信函"提醒。尽管公司已作出澄清与整改回应，但合规风险叠加此前ASCO催化剂兑现后的获利了结压力，股价持续承压。公司当前PE为负值，尚处于亏损状态，市场对其商业化前景的信心受到冲击。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.